These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 21161283)

  • 1. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.
    Lapeyraque AL; Frémeaux-Bacchi V; Robitaille P
    Pediatr Nephrol; 2011 Apr; 26(4):621-4. PubMed ID: 21161283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.
    Tschumi S; Gugger M; Bucher BS; Riedl M; Simonetti GD
    Pediatr Nephrol; 2011 Nov; 26(11):2085-8. PubMed ID: 21877169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.
    Mache CJ; Acham-Roschitz B; Frémeaux-Bacchi V; Kirschfink M; Zipfel PF; Roedl S; Vester U; Ring E
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1312-6. PubMed ID: 19556379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.
    Besbas N; Gulhan B; Karpman D; Topaloglu R; Duzova A; Korkmaz E; Ozaltin F
    Pediatr Nephrol; 2013 Jan; 28(1):155-8. PubMed ID: 22956028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.
    Dorresteijn EM; van de Kar NC; Cransberg K
    Pediatr Nephrol; 2012 Jul; 27(7):1193-5. PubMed ID: 22399074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutation
.
    Cho H; Lee Y
    Clin Nephrol; 2017 Jul; 88(1):52-56. PubMed ID: 28502324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
    Vilalta R; Lara E; Madrid A; Chocron S; Muñoz M; Casquero A; Nieto J
    Pediatr Nephrol; 2012 Dec; 27(12):2323-6. PubMed ID: 22890512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
    Tran H; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.